Physician
CLS Health PLLC
CLS Health PLLC was paid $1.87M by Medicaid between Jan 2018 and Dec 2024, across 88 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 24% of everything it billed.
33Billing provider infoCLS HEALTH PLLC
WEBSTER, TX 77598
WEBSTER, TX 77598
33aNPI1750305355assigned 07/27/2006
33bProvider typeVascular Surgery Physician
28Total paid$1.87M
24GClaims73,250
24DCodes billed88
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Vascular Surgery Physician providers in Texas
Rank by total paid#3 of 35
Median peer was paid$4K
This provider vs. median431×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 288 | $365.39 | |
| 2019 | 778 | $1K | |
| 2020 | 2,830 | $25K | |
| 2021 | 8,843 | $195K | |
| 2022 | 11,144 | $302K | |
| 2023 | 18,840 | $512K | |
| 2024incomplete | 30,527 | $839K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 24% | 10,762 | 8,204 | $442K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 16% | 1,953 | 1,770 | $304K |
| 99233 | Hospital visit by a doctor, follow-up day (complex)Prolong inpt eval add15 m | 8.1% | 4,998 | 1,567 | $153K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 5.9% | 707 | 622 | $111K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 4.4% | 2,145 | 1,937 | $83K |
| 99223 | Prolong inpt eval add15 m | 3.8% | 838 | 765 | $70K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 3.4% | 883 | 850 | $64K |
| 99232 | Hospital visit by a doctor, follow-up daySubsequent hospital care, per day, moderate complexity | 3.0% | 2,194 | 781 | $56K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 2.9% | 944 | 897 | $55K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | 2.9% | 444 | 439 | $55K |
| 87481 | 2.4% | 702 | 618 | $45K | |
| 99239 | Hospital discharge day management, more than 30 minutes | 2.1% | 792 | 733 | $39K |
76 more codes
| 59409 | Vaginal delivery only (with or without episiotomy and/or forceps) | 2.1% | 73 | $39K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 1.9% | 694 | $36K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | 1.9% | 328 | $35K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 1.7% | 471 | $32K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 422 | $21K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 383 | $18K |
| 92250 | <1% | 259 | $17K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 601 | $16K |
| 76830 | Ultrasound, transvaginal | <1% | 180 | $15K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 186 | $14K |
| 87529 | <1% | 487 | $12K | |
| 99220 | <1% | 141 | $10K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 220 | $10K |
| 92015 | Determination of refractive state | <1% | 579 | $9K |
| 87640 | <1% | 706 | $9K | |
| 87653 | <1% | 701 | $9K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 212 | $9K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 159 | $9K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 486 | $7K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 96 | $7K |
| 87511 | <1% | 487 | $6K | |
| G0659 | Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes | <1% | 126 | $5K |
| 81003 | <1% | 3,779 | $5K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 303 | $5K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 959 | $4K |
| 99217 | <1% | 105 | $4K | |
| S0621 | Routine ophthalmological examination including refraction; established patient | <1% | 73 | $4K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 56 | $3K |
| 87563 | <1% | 161 | $3K | |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 386 | $3K |
| 59025 | Fetal non-stress test | <1% | 81 | $2K |
| 99245 | <1% | 16 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 163 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 162 | $2K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 40 | $2K |
| 81025 | <1% | 360 | $2K | |
| 99225 | <1% | 56 | $1K | |
| 99254 | <1% | 14 | $1K | |
| 94760 | <1% | 5,309 | $1K | |
| 99255 | <1% | 12 | $1K | |
| 87500 | <1% | 79 | $1K | |
| 87641 | <1% | 79 | $895.19 | |
| S8301 | Infection control supplies, not otherwise specified | <1% | 20 | $485.50 |
| 93000 | <1% | 38 | $354.94 | |
| J3490 | Unclassified drugs | <1% | 47 | $334.60 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 29 | $229.70 |
| 93041 | <1% | 43 | $72.97 | |
| 81001 | <1% | 16 | $43.52 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 164 | $26.39 |
| A4248 | Chlorhexidine containing antiseptic, 1 ml | <1% | 107 | $19.58 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 45 | $16.12 |
| 80053 | Comprehensive metabolic panel | <1% | 14 | $12.17 |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 776 | $0.42 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 39 | $0.31 |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | <1% | 5,299 | $0.06 |
| 1036F | 0% | 763 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 320 | $0.00 |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 4,565 | $0.00 |
| 1111F | 0% | 381 | $0.00 | |
| G8419 | Bmi documented outside normal parameters, no follow-up plan documented, no reason given | 0% | 43 | $0.00 |
| G9902 | Patient screened for tobacco use and identified as a tobacco user | 0% | 347 | $0.00 |
| 36415 | Collection of venous blood by venipuncture | 0% | 108 | $0.00 |
| 99459 | 0% | 397 | $0.00 | |
| G8950 | Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented | 0% | 17 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 8,460 | $0.00 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 1,643 | $0.00 |
| G8783 | Normal blood pressure reading documented, follow-up not required | 0% | 496 | $0.00 |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | 0% | 243 | $0.00 |
| 4004F | 0% | 268 | $0.00 | |
| G8484 | Influenza immunization was not administered, reason not given | 0% | 696 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 197 | $0.00 |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 0% | 63 | $0.00 |
| G0029 | Tobacco screening not performed or tobacco cessation intervention not provided during the measurement period or in the six months prior to the measurement period | 0% | 17 | $0.00 |
| G8442 | Pain assessment not documented as being performed, documentation the patient is not eligible for a pain assessment using a standardized tool at the time of the encounter | 0% | 13 | $0.00 |
| 1159F | 0% | 12 | $0.00 | |
| 99490 | Ccm add 20min | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBABA, MOHAMMAD (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Infectious Diseases Clinic at Clear Lake Specialties PLLC | Webster, TX | $377K |
| Clear Lake Primary Care PLLC | Webster, TX | $311K |
| Endocrinology Clinic at Clear Lake Specialties PLLC | Webster, TX | $131K |
| Clear Lake Podiatry PLLC | Webster, TX | $129K |
| Clear Lake Cardiology PLLC | Webster, TX | $90K |
| Neurology Clinic at Clear Lake Specialties PLLC | Webster, TX | $31K |
| Clear Lake Wound Care PLLC | Webster, TX | $24K |
| South Texas Foot Specialist, PA | Friendswood, TX | $3K |
| Clear Lake Hospitalists PA | Webster, TX | $672.87 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.